Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".
CNS Drugs
; 36(12): 1333-1335, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36331781
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Attention Deficit Disorder with Hyperactivity
/
Viloxazine
/
Central Nervous System Stimulants
/
Methylphenidate
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
CNS Drugs
Journal subject:
FARMACOLOGIA
/
NEUROLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: